American College of Cardiology

DECEMBER 23, 2024

The goal of the SURMOUNT-1 trial was to assess the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist versus placebo in overweight or obese adults without diabetes.

Obesity 60

Obesity Diabetes Article 60

American College of Cardiology

MARCH 6, 2024

Bariatric surgery is effective in controlling hypertension (HTN) and polypharmacy in patients with obesity, according to results from the GATEWAY clinical trial published Feb. 5 in JACC.

Obesity 69

Obesity Hypertension Article 69

American College of Cardiology

JANUARY 2, 2024

The goal of the SURMOUNT-4 trial was to evaluate tirzepatide compared with placebo among obese patients.

Obesity 64

Obesity Article 64

American College of Cardiology

JUNE 4, 2024

The goal of the Dual vs. Single DCCV trial was to determine the efficacy and safety of dual direct-current cardioversion (DCCV) compared with single DCCV in patients with obesity and atrial fibrillation (AF) undergoing elective electrical cardioversion.

Obesity 58

Obesity Atrial Fibrillation Article 58

American College of Cardiology

AUGUST 7, 2024

He then explores obesity in adolescents and its impact on our societal health. In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition.

Obesity 61

Obesity Pulmonary Hypertension TAVR 61

American College of Cardiology

AUGUST 26, 2024

The goal of the STEP-HFpEF trial was to compare the safety and efficacy of semaglutide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 58

Preserved Ejection Fraction Obesity Heart Failure Article 58

American College of Cardiology

MARCH 25, 2025

Richard Chazal and Mikhail Kosiborod explore the rapidly evolving therapeutic landscape of obesity, with a particular focus on the cardiovascular benefits of emerging treatments. In this interview, Drs.

Obesity 56

Obesity Outcomes Article 56

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 61

Preserved Ejection Fraction Obesity Heart Failure Diabetes 61

American College of Cardiology

AUGUST 5, 2024

The following are key points to remember from a review on obesity in adolescents.

Obesity 53

Obesity Article 53

American College of Cardiology

MARCH 31, 2025

25 in Chicago and simultaneously published in JACC.

Preserved Ejection Fraction 64

Preserved Ejection Fraction Kidney Disease Obesity Heart Failure 64

American College of Cardiology

MAY 29, 2024

The following are key points to remember from an American Heart Association scientific statement on the implementation of obesity science into clinical practice.

Obesity 56

Obesity Article 56

Cardiology Update

DECEMBER 11, 2023

Previous studies have associated obesity with negative changes in the right ventricle using imaging techniques. However, the connection between obesity and more direct measures of right ventricle function, particularly those reflecting hemodynamic consequences, have been unclear. Original article: Circ Heart Fail.

Obesity 52

Obesity Hospital Outcomes Heart Failure 52

American College of Cardiology

JUNE 24, 2024

Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)

Preserved Ejection Fraction 66

Preserved Ejection Fraction Obesity Heart Failure Cardiomyopathy 66

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 69

Preserved Ejection Fraction Heart Failure Obesity Diabetes 69

American College of Cardiology

JANUARY 21, 2025

Overweight and obesity are common in patients with heterozygous familial hypercholesterolemia (HeFH) and are associated with a greater risk of atherosclerotic cardiovascular disease (ASCVD) starting in childhood and regardless of LDL-C level and lipid-lowering medication, according to a cross-sectional analysis published Jan.

Obesity 58

Obesity Cardiovascular Disease Article 58

American College of Cardiology

JUNE 24, 2024

The goal of the SURMOUNT-OSA trial was to determine the effect of tirzepatide, both alone and in the setting of positive airway pressure (PAP) therapy, on obstructive sleep apnea (OSA) burden in patients with obesity.

Obesity 56

Obesity Article 56

American College of Cardiology

JANUARY 29, 2025

He then discusses overweight and obesity in patients with familial hyperlipidemia. In this weeks View, Dr. Eagle examines the cost-effectiveness of polypills.

Obesity 58

Obesity Outcomes Article 58

American College of Cardiology

MARCH 12, 2024

What are the trends in the estimated prevalence of underweight and obesity from 1990 to 2022 among adults and children across 200 countries and territories?

Obesity 53

Obesity Article 53

American College of Cardiology

NOVEMBER 25, 2024

The following are key points to remember from a review on national- and state-level prevalence of overweight and obesity among children, adolescents, and adults in the United States (US), 1990–2021, and forecasts up to 2050.

Obesity 53

Obesity Article 53

Cardiometabolic Health Congress

JULY 25, 2023

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

American College of Cardiology

DECEMBER 14, 2023

The goal of the SELECT trial was to determine the association of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with cardiovascular (CV) events in a secondary prevention cohort of patients with overweight or obesity and prior CV disease (CVD) without diabetes mellitus (DM).

Obesity 56

Obesity Outcomes Diabetes Article 56

American College of Cardiology

JANUARY 15, 2025

Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF.

Preserved Ejection Fraction 50

Preserved Ejection Fraction Heart Failure Obesity Diabetes 50

American College of Cardiology

APRIL 3, 2025

The prevalence of obesity continues to rise, now at 40.3% adults, and doubled worldwide over the last forty years.

Obesity 40

Obesity Article 40

Physiologically Speaking

JANUARY 31, 2025

I plan to contribute articles and more to Marathon Handbook on a regular basis. The benefits derived from progression runs is also the topic of this article by Matt Fitzgerald, another training expert. I’ve just finished reading a half-dozen recent articles on processed foods. Thanks so much. I won’t be far away.

Physiology 85

Physiology Exercise Article Research 85

American College of Cardiology

NOVEMBER 16, 2024

The goal of the SUMMIT trial was to compare the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 50

Preserved Ejection Fraction Heart Failure Obesity Article 50

Hypertension Journal

NOVEMBER 8, 2023

Alterations in microcirculation play a crucial role in the pathogenesis of cardiovascular and metabolic disorders such as obesity and hypertension. In obesity, PVAT becomes enlarged and inflamed, and the bioavailability of adiponectin is reduced. Hypertension, Ahead of Print.

Obesity 40

Obesity Hypertension Blood Pressure Article 40

Dr. Paddy Barrett

AUGUST 9, 2024

The 14 Factors Include: Hearing Loss High LDL cholesterol Less Education Traumatic Brain Injury Depression Social Isolation Hypertension Obesity Smoking Excess Alcohol Diabetes Physical Inactivity Air Pollution Visual Loss Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission When You Intervene Matters.

Dementia 115

Dementia Blood Pressure Obesity Cholesterol 115

The British Journal of Cardiology

AUGUST 6, 2024

Obesity is a global pandemic and is a recognised risk factor for cardiovascular diseases. Therefore, we conducted an observational study with a cohort of 196 participants, comparing various echocardiographic parameters in normal weight individuals and those who were overweight or obese but had no other risk factors.

Obesity 40

Obesity Risk Factors Cardiovascular Disease Cardiac Function 40

The British Journal of Cardiology

OCTOBER 8, 2024

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering and weight-lowering agents used in the management of type 2 diabetes mellitus and obesity.

Obesity 40

Obesity Diabetes Kidney Disease Heart Failure 40

American College of Cardiology

NOVEMBER 27, 2024

In this week’s View, Dr. Eagle looks at the prevalence of overweight and obesity among children, adolescents, and adults in the U.S., with forecasts up to 2050.

Obesity 45

Obesity Article 45

American College of Cardiology

SEPTEMBER 26, 2024

Does semaglutide efficacy vary with baseline diuretic use and does semaglutide change diuretic dose in patients with heart failure with preserved ejection fraction (HFpEF)?

Preserved Ejection Fraction 64

Preserved Ejection Fraction Obesity Heart Failure Article 64

Journal of Cardiovascular Pharmacology

DECEMBER 11, 2023

The impact of severe obesity on weight-based heparin dosing is not well studied. Lower heparin dose (U/kg) was required in obese patients to achieve target ACT. In conclusion, there is significant variability in the therapeutic effect of heparin, with a lower weight-adjusted heparin dose required in obese patients.

Obesity 40

Obesity BMI Article 40

American College of Cardiology

JULY 1, 2024

What is the effect of semaglutide compared with placebo on N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure and preserved ejection fraction (HFpEF)?

Preserved Ejection Fraction 58

Preserved Ejection Fraction Obesity Heart Failure Article 58

Circulation

SEPTEMBER 2, 2024

Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Quality of Life Article Heart Failure 45

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′. Overall, 60.9%

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

European Journal of Heart Failure

DECEMBER 13, 2023

Association between epicardial adipose tissue (EAT) and cardiac dysfunction in severe obesity. Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heart failure with preserved ejection fraction. BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain. p  = 0.045).

Obesity 40

Obesity Preserved Ejection Fraction BMI Heart Failure 40

International Journal of Cardiovascular Sciences

MARCH 13, 2023

The International Journal of Cardiovascular Science (IJCS) is accepting articles for a special thematic issue focusing on cardiometabolic diseases, to be published in September 2023. These factors include obesity, dyslipidemia, hypertension, and insulin resistance — also known as metabolic syndrome.

Pharmacology 52

Pharmacology Article Obesity Risk Factors 52